• ASHWANI KUMAR Department of Biochemistry, Government Medical College and Rajindra Hospital, Patiala, Punjab, India.
  • ANJLEEN KAUR Department of Surgery, Government Medical College and Rajindra Hospital, Patiala, Punjab, India.



CA19-9, Pancreaticobiliary carcinoma, Metastatic disease


Objective: This study was designed and conducted to establish the relationship of biomarker CA19-9 levels in pancreaticobiliary and gastrointestinal malignancies.

Methods: 50 patients with confirmed diagnosis of pancreaticobiliary and gastrointestinal malignancies and 30 age and gender matched controls were included in the study. Serum values of CA19-9 were determined in patients before surgery and chemotherapy.

Results: In our present study, maximum number of patients were in the age group of 51–60 years. Mean levels of serum CA19-9 in patients (n=50) are 146.28±156.87 U/mL. Total patients (n=50), in 19 patients CA19-9 levels were ≤37 U/mL and in 31 patients CA19-9 levels were >37 U/mL. CA19-9 levels were highest in pancreatic and cholangiocarcinoma.

Conclusion: High sensitivity and specificity of CA19-9 in pancreatic and biliary tract tumors identified CA19-9 as a best validated biomarker.


Download data is not yet available.


Corrigan LR, Bracken-Clarke DM, Horgan AM. The challenge of treating older patients with pancreaticobiliary malignancies. Curr Probl Cancer 2018;42:59-72. doi: 10.1016/j.currproblcancer.2018.01.015, PMID 29459178

Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17. doi: 10.1056/NEJMra0901557, PMID 20427809

Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: Yesterday, today and tomorrow. Future Oncol 2016;12:1929-46. doi: 10.2217/fon-2016-0010, PMID 27246628

Ashai N, Prasad P, Rajdev L. Multimodality management of localized biliary cancer. Curr Treat Options Oncol 2019;20:58. doi: 10.1007/ s11864-019-0655-0, PMID 31144050

Copur MS, Merani S, Vargas LM. Biliary cancer: Current multimodality treatment and future directions. Oncol (Williston Park) 2019;33:685003. PMID 685003

Malati T. Tumour markers: An overview. Indian J Clin Biochem 2007;22:17-31. doi: 10.1007/BF02913308, PMID 23105677

Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract 2013;22:4-11. doi: 10.1159/000338393, PMID 22584792

Hoskovec D, Varga J, Konečná E, Antos F. Levels of CEA and Ca 19-9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers. Acta Cir Bras 2012;27:410-6. doi: 10.1590/s0102- 86502012000600009, PMID 22666759

Bertino G, Ardiri AM, Calvagno GS, Malaguarnera G, Interlandi D, Vacante M, et al. Carbohydrate 19.9 antigen serum levels in liver disease. BioMed Res Int 2013;2013:531640. doi: 10.1155/2013/531640

Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, et al. CA19-9 for detecting recurrence of pancreatic cancer [sci rep:1332]. Sci Rep 2020;10:1332. doi: 10.1038/s41598-020-57930-x, PMID 31992753

Guo X, Yamada S, Omori H, Wang KY, Tasaki T, Nabeshima A, et al. CA19-9 producing early gastric adenocarcinoma arising in hyperplastic foveolar polyp: A very unique resection case. Diagn Pathol 2011;6:112. doi: 10.1186/1746-1596-6-112, PMID 22070794

Ugorski M, Laskowska A, Lewis S. Sialyl Lewis(a): A tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002;49:303-11. doi: 10.18388/ abp.2002_3788, PMID 12362971

Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. doi: 10.1016/j. bbcan.2020.188409

Song YX, Huang XZ, Gao P, Sun JX, Chen XW, Yang YC, et al. Clinicopathologic and prognostic value of serum carbohydrate antigen 19-9 in gastric cancer: A meta-analysis. Dis Markers 2015;2015:549843. doi: 10.1155/2015/549843

Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, et al. CA19-9 normalisation during preoperative treatment predicts longer survival for patients with locally progressed pancreatic cancer. J Gastrointest Surg 2016;20:1331-42. doi: 10.1007/s11605-016- 3149-4, PMID 27114246

Takahara N, Nakai Y, Isayama H, Sasaki T, Saito K, Noguchi K, et al. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer. Cancer Chemother Pharmacol 2017;80:1105-12. doi: 10.1007/s00280-017-3456-9, PMID 29038848

Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology 2018;18:862-7. doi: 10.1016/j. pan.2018.09.004, PMID 30249386

Sachan A, Saluja SS, Nekarakanti PK, Nimisha MB, Mahajan B, Nag HH, et al. Raised CA19-9 and CEA have prognostic relevance in gallbladder carcinoma. BMC Cancer 2020;20:826. doi: 10.1186/ s12885-020-07334-x, PMID 32867709

Yamashita K, Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 2009;100:195-9. doi: 10.1111/j.1349-7006.2008.01022.x, PMID 19200256

Gür T, Demir H, Kotan MÇ. Tumor markers and biochemical parameters in colon cancer patients before and after chemotherapy. Asian Pac J Cancer Prev 2011;12:3147-50. PMID 22394005



How to Cite

MITTAL, D., J. SINGH, M. KAUR, A. KUMAR, and A. KAUR. “TO ESTIMATE THE LEVELS OF CA19-9 AND ITS SIGNIFICANCE IN DIAGNOSIS AND TREATMENT OF PANCREATICOBILIARY AND GASTROINTESTINAL MALIGNANCIES”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 5, May 2022, pp. 125-7, doi:10.22159/ajpcr.2022.v15i5.44365.



Original Article(s)